Dr. Suxia Luo 罗素霞
Chief Physician
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of malignant tumors, including digestive tract cancers, breast cancer, lymphoma, and lung cancer. Focuses on individualized treatment and research for digestive tract tumors and breast cancer.
Dr. Luo is a Chief Physician, Deputy Director of the Henan Provincial Tumor Disease Control Center, and holds a medical doctorate. A doctoral supervisor and recipient of the State Council Special Allowance, Dr. Luo has authored six monographs and published over 100 academic papers. Research funding includes more than 20 national and provincial projects, with seven Henan Provincial Science and Technology Progress Awards.
Professional roles
- Member, Chinese Medical Association
- Chair, Henan Province Tumor Rehabilitation Professional Committee
- Vice Chair, Henan Province Clinical Chemotherapy Professional Committee
- Vice Chair, Henan Province Medical Association Oncology Professional Committee
Name order: in Chinese the family name comes first (Luo Suxia). Papers usually list the name as Suxia Luo or Luo S.
Selected publications
148 papers on PubMed matched by name and affiliation; 55 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Biochem Mol Toxicol, 2026 (senior author): XDH Inhibits the Progression of Colorectal Cancer via Regulating Ferritinophagy Signaling. PubMed 42927618
- Signal Transduct Target Ther, 2024 (senior author): First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study. PubMed 39511164
- Sci Rep, 2024 (senior author): Oxaliplatin-induced upregulation of exosomal miR-424-3p derived from human bone marrow mesenchymal stem cells attenuates progression of gastric cancer cells. PubMed 39090292
- Clin Exp Med, 2024 (senior author): Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma. PubMed 38884870
- Int J Surg, 2024 (senior author): Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. PubMed 38320099
- J Biochem Mol Toxicol, 2023 (senior author): Long noncoding RNA ZEB1-AS1 attenuates ferroptosis of gastric cancer cells through modulating miR-429/BGN axis. PubMed 37128782
- J Gastrointest Oncol, 2023 (senior author): Identification of a potential competing endogenous RNA (ceRNA) network in gastric adenocarcinoma. PubMed 37201096
- Sci Rep, 2023 (senior author): Prognostic impact of examined lymph-node count for patients with esophageal cancer: development and validation prediction model. PubMed 36627338
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion